ID   KTCTL-140
AC   CVCL_5879
SY   KTCTL140; RCC-JF; RCCJF
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_5879
DR   Cell_Model_Passport; SIDM00818
DR   CLS; 300274
DR   Cosmic; 972926
DR   Cosmic; 1352063
DR   Cosmic; 1751974
DR   Cosmic-CLP; 1524415
DR   DepMap; ACH-002190
DR   EGA; EGAS00001000978
DR   GDSC; 1524415
DR   PharmacoDB; RCCJF_1290_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54900633
RX   PubMed=7915601;
RX   PubMed=11762795;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.His115Tyr (c.343C>T); dbSNP=rs5030811; Zygosity=Unspecified (PubMed=7915601).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.77%; East Asian, North=2.03%; East Asian, South=0%; South Asian=1.72%; European, North=62.07%; European, South=33.41% (PubMed=30894373).
CC   Misspelling: KTCL140; Cosmic=972926; PubMed=7915601.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): CLS; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 10,13
ST   D13S317: 11,12
ST   D16S539: 11
ST   D18S51: 13,15
ST   D21S11: 28,30.2
ST   D3S1358: 17
ST   D5S818: 11
ST   D7S820: 7,8
ST   D8S1179: 12,14
ST   FGA: 18,25
ST   Penta D: 10,13
ST   Penta E: 7,13
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 31
//
RX   PubMed=7915601; DOI=10.1038/ng0594-85;
RA   Gnarra J.R., Tory K., Weng Y., Schmidt L.S., Wei M.H., Li H., Latif F.,
RA   Liu S., Chen F., Duh F.-M., Lubensky I.A., Duan D.R., Florence C.,
RA   Pozzatti R., Walther M.M., Bander N.H., Grossman H.B., Brauch H.,
RA   Pomer S., Brooks J.D., Isaacs W.B., Lerman M.I., Zbar B.,
RA   Linehan W.M.;
RT   "Mutations of the VHL tumour suppressor gene in renal carcinoma.";
RL   Nat. Genet. 7:85-90(1994).
//
RX   PubMed=11762795; DOI=10.1007/s002400100214;
RA   Siebels M., Meyer G., Habicht A., Meuer S.C., Moebius U.;
RT   "Simultaneous ligation of CD5 and CD28 with monoclonal antibodies
RT   restores impaired immunostimulatory function in human renal cell
RT   carcinoma.";
RL   Urol. Res. 29:330-337(2001).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//